HeartBeam Inc. (NASDAQ: BEAT) is collaborating with Mount Sinai to advance artificial intelligence-driven electrocardiogram (ECG) technology, a move that underscores the growing importance of AI in healthcare and remote patient monitoring. The partnership, highlighted in a recent article, focuses on developing and validating high-value AI-based ECG algorithms that can be deployed across HeartBeam's platform. These algorithms may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.
The collaboration aims to leverage HeartBeam's innovative cable-free 12-lead ECG technology, which captures the heart's electrical signals from three dimensions, enabling portable and actionable cardiac intelligence. By integrating AI, the platform can identify cardiac health trends and acute conditions, allowing physicians to direct patients to appropriate care outside traditional medical facilities. This aligns with the broader healthcare shift toward data-driven, remote monitoring solutions.
HeartBeam holds 13 U.S. and 4 international-issued patents related to its technology, positioning it as a key player in cardiac care innovation. The company's platform is designed for use in portable devices, delivering actionable heart intelligence wherever the patient is. The partnership with Mount Sinai, a renowned academic medical center, is expected to accelerate the development and validation of these AI algorithms, potentially improving outcomes for patients with cardiac conditions.
For more details on the collaboration, the full article can be accessed at https://ibn.fm/oTJHB. Additional information about HeartBeam is available at www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
